MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
cepii_allergie.png
 
 
 
Hauptnavigation
  • Home
  • Allgemeine Informationen
  • Forschung
  • Studium & Lehre
  • FachärztInnenausbildung
 
IPA / Single View
 
Subnavigation

Research News

 

Isolation of nanobodies with potential to reduce patients' IgE binding to the major birch pollen allergen, Bet v 1

Ines Zettl, Tatiana Ivanova, Maria R. Strobl, Christina Weichwald, Oksana Goryainova, Evgenia Khan, Marina V. Rutovskaya, Margarete Focke- Tejkl, Anja Drescher, Barbara Bohle, Sabine Flicker, Sergei V. Tillib Allergy 2022...[more]

 

Impaired Mineral Ion Metabolism in a Mouse Model of Targeted Calcium-Sensing Receptor (CaSR) Deletion from Vascular Smooth Muscle Cells

Martin Schepelmann (group Enikö Kallay) and national and international colleagues and collaborators have just published a study in the Journal of the American Society of Nephrology (JASN), one of the highest ranked and most...[more]

 

Vaccine based on folded RBD-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants

The preclinical data for a vaccine developed at MedUni Vienna to protect against SARS-CoV-2 indicates that it is effective against all SARS-CoV-2 variants known to date, including omicron - even in those who have not yet built up...[more]

 

Birch pollen allergic patients have IgE and IgG antibodies binding to diverse patterns of conformational epitopes on the major allergen, Bet v 1

Schmalz S, Mayr V, Shosherova A, Gepp B, Ackerbauer D, Sturm G, Bohle B, Breiteneder H, Radauer C. Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1.[more]

 

Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.

Gattinger P, Niespodziana K, Stiasny K, Sahanic S, Tulaeva I, Borochova K, Dorofeeva Y, Schlederer T, Sonnweber T, Hofer G, Kiss R, Kratzer B, Trapin D, Tauber PA, Rottal A, Körmöczi U, Feichter M, Weber M, Focke-Tejkl M,...[more]

 

Stereo-Specific Modulation of the Extracellular Calcium-Sensing Receptor in Colon Cancer Cells

Martin Schepelmann, Nadja Kupper, Marta Sladczyk, Bethan Mansfield, Teresa Manhardt, Karina Piatek, Luca Iamartino, Daniela Riccardi, Benson M. Kariuki, Marcella Bassetto, and Enikö Kallay Stereo-Specific Modulation of the...[more]

 

Amirreza Mahbod, Post-Doc in the group of Isabella Ellinger, has achieved PLACE 1 in the leaderboard of the MICCAI 2021 Foot Ulcer Segmentation Challenge.

Foot ulcer is a common complication of diabetes mellitus; it is associated with substantial morbidity and mortality and remains a major risk factor for lower leg amputation. Extracting accurate morphological features from the...[more]

 
Displaying results 1 to 7 out of 96
<< First < Previous 1 2 3 4 5 6 7 Next > Last >>
 
Inhaltsbereich

Taking systems biology to ovarian cancer

A study published in Computational and Structural Biotechnology Journal and conducted by Anastasia Meshcheryakova from the Systems Biology and Pathophysiology Group of Diana Mechtcheriakova together with colleagues from the Medical University of Vienna and the multidisciplinary team of international experts made an effort to look from another angle on potential therapeutic checkpoints for epithelial ovarian cancer and propose that assessment of the sphingolipid and lysophosphatidate systems in conjunction with the local immune response may lead to novel stratifying and targeting strategies. This offers the power for improving the efficacy of existing therapies and possibly immunotherapies.

The major clinical challenge of high-grade serous ovarian cancer is an ultimate development of progressive resistance to chemotherapy in the majority of patients. A further distinctive cornerstone is the high inter- and intra-tumoral genetic, inflammatory, and immune heterogeneity. In contrast to other cancer types, there is a lack of clear molecular criteria to stratify (group) the patients for effective application of molecular-targeted agents, including immunotherapeutic interventions.

Diana Mechtcheriakova, Head Molecular Systems Biology and Pathophysiology Group, the project leader: “In this study, we provide a novel approach to this challenge based on the understanding of the dysregulation of the sphingolipid signaling system that occurs in cancer, its crosstalk with the lysophosphatidate system, and the interrelation with the local tumor immune microenvironment. And yet, at the same time, we consider that the complexity of the sphingolipid system multiplied by the heterogeneity of tumor necessitates the implementation of integrative, systems biology-based approaches for analysis and for obtaining a comprehensive picture.”

The authors implemented a multi-modular integrative approach, recently developed by Diana Mechtcheriakova’s research group (Department of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University of Vienna) in collaboration with Georg Heinze (Section for Clinical Biometrics, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna), Philip Zimmermann (Nebion AG, Zürich, Switzerland), and Markus Jaritz (Research Institute of Molecular Pathology, Vienna Biocenter). The algorithm was named as MuSiCO/from Multigene Signature to Patient-Orientated Clinical Outcome. This innovative approach consolidates the latest accomplishments in gene expression profiling, prognostic/predictive modeling, next generation digital pathology, and systems biology.

The authors applied the self-created sphingolipid/lysophosphatidate/immune-associated multigene signature within the integrative 5-modular MuSiCO algorithm and demonstrated the applicability of the patient-specific, signature-derived gene expression data sets for identification of novel sphingolipid/lysophosphatidate/immune-related, disease-relevant aberrations and checkpoints. The comprehensiveness of analysis was herein strengthened by inclusion of next generation digital pathology/digital imaging module and by a compendium-wide analysis for assessment of specificity of the herein defined transcriptional profile across the signature genes. 

The results and new algorithm provide unique knowledge about the complex expression patterns of sphingolipid-related genes as well as relationships among sphingolipid-, lysophosphatidate-, and immune-related genes. The data presented in this study indicate that the features of the program established by the local sphingolipid/lysophosphatidate machinery give an important impact to the organization of the ovarian cancer microenvironment by way of shaping immune infiltrates. Important follow-up is that the acquired information delivers novel patient-stratification strategies for differentiating between immunologically enriched/immune high and immunologically poor/immune low tumor types and for predicting the clinical outcomes of survival and drug resistance. The study identifies sphingolipid/lysophosphatidate/immune-associated checkpoints as candidates for development of novel targeting and clinical decision-making strategies.

Article:

Meshcheryakova A, Svoboda M, Jaritz M, Mungenast F, Salzmann M, Pils D, Castillo-Tong DC, Hager G, Wolf A, Braicu EI, Sehouli J, Lambrechts S, Vergote I, Mahner S, Birner P,  Zimmermann P, Brindley DN, Heinze G, Zeillinger R, Mechtcheriakova D. Interrelations of sphingolipid and lysophosphatidate signaling with immune system in ovarian cancer. Comput Struct Biotechnol J 2019, 17: 537-560. DOI:10.1016/j.csbj.2019.04.004

Link to publication

www.ncbi.nlm.nih.gov/pmc/articles/PMC6479272/

 
 
Drucken
 

Schnellinfo

 
-- Green IPA
-- Technology Platforms
-- Kontakt
-- News (Archiv)
-- Seminare
-- Social Life
-- Intranet Login
-- QM-Dokumente (Intranet)
-- Bildergalerie (Intranet)
-- Alumni
-- Links
 
 

Featured

 
 
 
© MedUni Wien  | 
 Impressum | Nutzungsbedingungen | Datenschutzerklärung | Barrierefreiheit | Kontakt